{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:43:03Z","timestamp":1792669383256,"version":"4.5.0"},"reference-count":30,"publisher":"MyJove Corporation","issue":"135","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/57530","type":"journal-article","created":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T20:00:07Z","timestamp":1526068807000},"source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts"],"prefix":"10.3791","author":[{"given":"Rika","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Touznik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2018,5,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12703\/P7-04","type":"journal-article","article-title":"Spinal muscular atrophy: from tissue specificity to therapeutic strategies","volume":"7","author":"Iascone","year":"2015","unstructured":"Iascone, D. M., Henderson, C. E., & Lee, J. C. Spinal muscular atrophy: from tissue specificity to therapeutic strategies. F1000Prime Rep. 7 04 (2015).","journal-title":"F1000Prime Rep"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14712598.2014.896335","type":"journal-article","article-title":"New developments in exon skipping and splice modulation therapies for neuromuscular diseases","volume":"14","author":"Touznik","year":"2014","unstructured":"Touznik, A., Lee, J. J., & Yokota, T. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther. 14 (6), 809-819 (2014).","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","type":"journal-article","article-title":"Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene","volume":"80","author":"Lefebvre","year":"1995","unstructured":"Lefebvre, S. et al. Identification and Characterization of a Spinal Muscular Atrophy-Determining Gene. Cell. 80 (1), 155-165 10.1016\/0092-8674(95)90460-3, (1995).","journal-title":"Cell"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","type":"journal-article","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","unstructured":"Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 96 (11), 6307-6311 (1999).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","type":"journal-article","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","unstructured":"Monani, U. R. et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 8 (7), 1177-1183 (1999).","journal-title":"Hum Mol Genet"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jpm3030144","type":"journal-article","article-title":"Antisense therapy in neurology","volume":"3","author":"Lee","year":"2013","unstructured":"Lee, J. J., & Yokota, T. Antisense therapy in neurology. J Pers Med. 3 (3), 144-176 (2013).","journal-title":"J Pers Med"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2017.0665","type":"journal-article","article-title":"FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides","volume":"27","author":"Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid Ther. 27 (2), 67-69 (2017).","journal-title":"Nucleic Acid Ther"},{"issue":"7367","key":"ref8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature10485","type":"journal-article","article-title":"Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model","volume":"478","author":"Hua","year":"2011","unstructured":"Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 478 (7367), 123-126 (2011).","journal-title":"Nature"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1371\/journal.pbio.0050073","type":"journal-article","article-title":"Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon","volume":"5","author":"Hua","year":"2007","unstructured":"Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 5 (4), e73 (2007).","journal-title":"PLoS Biol"},{"issue":"72","key":"ref10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","type":"journal-article","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","unstructured":"Passini, M. A. et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 3 (72), 72ra18 (2011).","journal-title":"Sci Transl Med"},{"issue":"39","key":"ref11","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","type":"journal-article","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","unstructured":"Hammond, S. M. et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A. 113 (39), 10962-10967 (2016).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","type":"journal-article","article-title":"A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse","volume":"21","author":"Porensky","year":"2012","unstructured":"Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 21 (7), 1625-1638 (2012).","journal-title":"Hum Mol Genet"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","type":"journal-article","article-title":"LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts","volume":"7","author":"Touznik","year":"2017","unstructured":"Touznik, A., Maruyama, R., Hosoki, K., Echigoya, Y., & Yokota, T. LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep. 7 (1), 3672 (2017).","journal-title":"Sci Rep"},{"issue":"50","key":"ref14","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","type":"journal-article","article-title":"Synthesis of 2'-O,4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C-3,-endo sugar puckering","volume":"38","author":"Obika","year":"1997","unstructured":"Obika, S. et al. Synthesis of 2'-O,4'-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C-3,-endo sugar puckering. Tetrahedron Letters. 38 (50), 8735-8738 10.1016\/S0040-4039(97)10322-7, (1997).","journal-title":"Tetrahedron Letters"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1039\/a708608c","type":"journal-article","article-title":"LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition","author":"Singh","year":"1998","unstructured":"Singh, S. K., Nielsen, P., Koshkin, A. A., & Wengel, J. LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chemical Communications. (4), 455-456 10.1039\/a708608c, (1998).","journal-title":"Chemical Communications"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cca.2014.10.017","type":"journal-article","article-title":"Real-time PCR detection chemistry","volume":"439","author":"Navarro","year":"2015","unstructured":"Navarro, E., Serrano-Heras, G., Castano, M. J., & Solera, J. Real-time PCR detection chemistry. Clin Chim Acta. 439 231-250 (2015).","journal-title":"Clin Chim Acta"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"13259","DOI":"10.3390\/ijms160613259","type":"journal-article","article-title":"Small RNA Detection by in Situ Hybridization Methods","volume":"16","author":"Urbanek","year":"2015","unstructured":"Urbanek, M. O., Nawrocka, A. U., & Krzyzosiak, W. J. Small RNA Detection by in Situ Hybridization Methods. Int J Mol Sci. 16 (6), 13259-13286 (2015).","journal-title":"Int J Mol Sci"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","type":"journal-article","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","unstructured":"Wahlestedt, C. et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A. 97 (10), 5633-5638 (2000).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","type":"journal-article","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","unstructured":"Rupaimoole, R., & Slack, F. J. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16 (3), 203-222 (2017).","journal-title":"Nat Rev Drug Discov"},{"issue":"5962","key":"ref20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1126\/science.1178178","type":"journal-article","article-title":"Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection","volume":"327","author":"Lanford","year":"2010","unstructured":"Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 327 (5962), 198-201 (2010).","journal-title":"Science"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","type":"journal-article","article-title":"Designing Effective Antisense Oligonucleotides for Exon Skipping","volume":"1687","author":"Shimo","year":"2018","unstructured":"Shimo, T., Maruyama, R., & Yokota, T. Designing Effective Antisense Oligonucleotides for Exon Skipping. Methods Mol Biol. 1687 143-155 (2018).","journal-title":"Methods Mol Biol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1093\/nar\/gku512","type":"journal-article","article-title":"Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro","volume":"42","author":"Shimo","year":"2014","unstructured":"Shimo, T. et al. Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res. 42 (12), 8174-8187 (2014).","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jpm7040013","type":"journal-article","article-title":"Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy","volume":"7","author":"Nguyen","year":"2017","unstructured":"Nguyen, Q., & Yokota, T. Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy. J. Pers. Med. 7 (4), 13 (2017).","journal-title":"J. Pers. Med"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.07.014","type":"journal-article","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","author":"Echigoya","year":"2017","unstructured":"Echigoya, Y. et al. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Mol Ther. (2017).","journal-title":"Mol Ther"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"12239","DOI":"10.1371\/journal.pone.0012239","type":"journal-article","article-title":"Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient","volume":"5","author":"Saito","year":"2010","unstructured":"Saito, T. et al. Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One. 5 (8), e12239 (2010).","journal-title":"PLoS One"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.nbd.2011.12.018","type":"journal-article","article-title":"Characterization of a murine model of SMA","volume":"45","author":"Donnelly","year":"2012","unstructured":"Donnelly, E. M. et al. Characterization of a murine model of SMA. Neurobiol Dis. 45 (3), 992-998 (2012).","journal-title":"Neurobiol Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","type":"journal-article","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","unstructured":"Lim, K. R., Maruyama, R., & Yokota, T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 11 533-545 (2017).","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1358\/dot.2017.53.6.2652413","type":"journal-article","article-title":"Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy","volume":"53","author":"Paton","year":"2017","unstructured":"Paton, D. M. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today (Barc). 53 (6), 327-337 (2017).","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"ref29","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/jm701537z","type":"journal-article","article-title":"Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides","volume":"51","author":"Prakash","year":"2008","unstructured":"Prakash, T. P. et al. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides. J Med Chem. 51 (9), 2766-2776 (2008).","journal-title":"J Med Chem"},{"issue":"34","key":"ref30","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1073\/pnas.1204638109","type":"journal-article","article-title":"Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery","volume":"109","author":"Aoki","year":"2012","unstructured":"Aoki, Y. et al. Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A. 109 (34), 13763-13768 (2012).","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/video\/57530\/evaluation-exon-inclusion-induced-splice-switching-antisense","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:15:18Z","timestamp":1792667718000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/57530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,11]]},"references-count":30,"journal-issue":{"issue":"135","published-online":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.3791\/57530","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,11]]}}}